Comparative Pharmacology
Head-to-head clinical analysis: ETHINYL ESTRADIOL ETONOGESTREL versus NORGESTIMATE ETHINYL ESTRADIOL.
Head-to-head clinical analysis: ETHINYL ESTRADIOL ETONOGESTREL versus NORGESTIMATE ETHINYL ESTRADIOL.
ETHINYL ESTRADIOL; ETONOGESTREL vs NORGESTIMATE; ETHINYL ESTRADIOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETHINYL ESTRADIOL is an estrogen; ETONOGESTREL is a progestin. The combination suppresses gonadotropin (FSH and LH) release from the pituitary, inhibiting ovulation, thickening cervical mucus to impede sperm penetration, and altering endometrial receptivity.
Combination oral contraceptive containing norgestimate (a progestin) and ethinyl estradiol (an estrogen). The primary mechanism is suppression of gonadotropins (FSH and LH) via negative feedback on the hypothalamic-pituitary-ovarian axis, preventing ovulation. Additional effects include thickening cervical mucus (inhibiting sperm penetration) and altering endometrial receptivity.
One vaginal ring (0.120 mg etonogestrel/0.015 mg ethinyl estradiol per day) inserted vaginally and left in place for 3 weeks, followed by a 1-week ring-free period.
Oral, one tablet daily at the same time for 21 days, followed by 7 placebo tablets.
None Documented
None Documented
Ethinyl estradiol: ~13 hours (range 7-20 h); etonogestrel: ~25 hours (range 15-36 h). At steady state, elimination half-life extends to 20-30 h for etonogestrel.
Norgestimate: terminal half-life of norelgestromin (active metabolite) is 27.6 ± 7.8 hours; ethinyl estradiol: terminal half-life is 17.5 ± 6.3 hours. Steady state achieved within 14 days.
Urine (60-70% as metabolites, <10% unchanged), feces (20-30% via biliary elimination).
Norgestimate metabolites are primarily excreted via urine (60-80%) and feces (35-49%) as glucuronide and sulfate conjugates; ethinyl estradiol is excreted in urine (40%) and feces (60%) as conjugates.
Category D/X
Category D/X
Progestin
Progestin + Estrogen